Limits...
Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.

Lin CS, Kao SH, Chen YC, Li CH, Hsieh YT, Yang SC, Wu CJ, Lee RP, Liao KW - Biol Proced Online (2012)

Bottom Line: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA.How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan. liaonms@pchome.com.tw.

ABSTRACT

Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.

Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.

Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.

No MeSH data available.


Related in: MedlinePlus

In vivo tumor development of BALB/c mice after oral vaccination. Five BALB/c mice in each treatment group were inoculated with CT26/CEA cells 21 days after vaccination with pCEA- and pCEA-SARS-transformed S. typhimurium and the tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298716&req=5

Figure 3: In vivo tumor development of BALB/c mice after oral vaccination. Five BALB/c mice in each treatment group were inoculated with CT26/CEA cells 21 days after vaccination with pCEA- and pCEA-SARS-transformed S. typhimurium and the tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).

Mentions: To determine the efficacy of the pCEA-SARS-CoV tumor vaccine, mice were orally immunized with 1 × 108 pCEA- and pCEA-SARS-CoV-transformed S. typhimurium 14 days before inoculation with colon cancer CT26/CEA cells. As per the data shown in Figure 3, the tumor volume was significantly lower in the pCEA-SARS-CoV group (p < 0.05) as compared with the pCEA group, indicating that the SARS fragment provided sufficient protection against the development of tumors.


Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.

Lin CS, Kao SH, Chen YC, Li CH, Hsieh YT, Yang SC, Wu CJ, Lee RP, Liao KW - Biol Proced Online (2012)

In vivo tumor development of BALB/c mice after oral vaccination. Five BALB/c mice in each treatment group were inoculated with CT26/CEA cells 21 days after vaccination with pCEA- and pCEA-SARS-transformed S. typhimurium and the tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298716&req=5

Figure 3: In vivo tumor development of BALB/c mice after oral vaccination. Five BALB/c mice in each treatment group were inoculated with CT26/CEA cells 21 days after vaccination with pCEA- and pCEA-SARS-transformed S. typhimurium and the tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).
Mentions: To determine the efficacy of the pCEA-SARS-CoV tumor vaccine, mice were orally immunized with 1 × 108 pCEA- and pCEA-SARS-CoV-transformed S. typhimurium 14 days before inoculation with colon cancer CT26/CEA cells. As per the data shown in Figure 3, the tumor volume was significantly lower in the pCEA-SARS-CoV group (p < 0.05) as compared with the pCEA group, indicating that the SARS fragment provided sufficient protection against the development of tumors.

Bottom Line: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA.How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan. liaonms@pchome.com.tw.

ABSTRACT

Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development.

Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-α and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.

Conclusion: The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.

No MeSH data available.


Related in: MedlinePlus